PharmaEngine announces first patient dosed in Phase I trial of PEP07 for hematological cancers
PharmaEngine announces EMA’s acceptance of ONIVYDE®’s Type II Variation application
PharmaEngine files post-approval change application for a new indication of ONIVYDE® to TFDA
PharmaEngine announces Phase 1 clinical study of PEP07 has been approved by Taiwan Food and Drug Administration (TFDA)
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Australia HREC and acknowledged by Australia TGA
PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL (6th Annual DDR Inhibitors Summit 2023)
Onivyde® regimen (NALIRIFOX) demonstrated statistically significant improvement in overall survival in 1L PDAC(Supplementary information)
Positive Topline Results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
PharmaEngine, Inc. Exercised Option for a Worldwide Exclusive License Agreement to Sentinel Oncology Limited’s CHK1 inhibitor
The Results from Phase III RESILIENT trial of irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (2L SCLC)
China NMPA Approves ONIVYDE Regimen for the Treatment of Metastatic Pancreatic Cancer Following Gemcitabine Based Therapy
PharmaEngine, Inc. Announces First Results for ONIVYDE® in Combination with LONSURF® in Refractory Solid Tumors at 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2022)
PharmaEngine and Nanobiotix to Terminate Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3
PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021